To read a message from our CEO regarding COVID-19, please click here.
Pain is complex. To support successful long-term outcomes, providers need the most programming solutions, excellent patient support, and the broadest clinical evidence. That’s why Nevro is committed to giving you more.
Treating pain requires flexibility and persistence. Nevro introduces Senza® Omnia™, the first and only spinal cord stimulation (SCS) system designed to deliver Nevro's proprietary HF10® therapy and all other frequencies in a single product.
To better support patients, NevroCloud™ closely links physicians and patients with their Nevro care team allowing comprehensive programming and outcomes histories to be shared with the practice.
Nevro systems offer the most waveforms in a single product and can be programmed to provide HF10 therapy independently or paired with other waveforms, enabling dual mechanisms of action that no other system can offer.
Nevro pursues clinical research to better support healthcare providers in treating chronic pain. No other SCS technology has this wealth of quality clinical data to back its technology.
At Nevro, our success is measured by our patient’s satisfaction. 88% percent of patients treated with HF10 therapy are more independent because of their reduced pain.1
Access to the clinical evidence portfolio supporting our therapy
Instructions for use and product manuals, including MRI guidelines
1. Calculated from patient survey data and functionality measures within the SENZA-RCT. Data on file.